ImmunoGen (NASDAQ:IMGN) has earned an average recommendation of “Hold” from the eleven analysts that are covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $11.60.
IMGN has been the subject of a number of research analyst reports. HC Wainwright set a $18.00 target price on shares of ImmunoGen and gave the stock a “buy” rating in a research report on Monday, February 12th. BidaskClub raised shares of ImmunoGen from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 9th. Zacks Investment Research downgraded shares of ImmunoGen from a “buy” rating to a “hold” rating in a research report on Wednesday, February 14th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $12.00 target price on shares of ImmunoGen in a research report on Thursday, February 8th. Finally, Cantor Fitzgerald set a $5.00 target price on shares of ImmunoGen and gave the stock a “hold” rating in a research report on Sunday, March 25th.
NASDAQ:IMGN opened at $10.25 on Friday. The company has a quick ratio of 4.94, a current ratio of 4.95 and a debt-to-equity ratio of -0.11. ImmunoGen has a 12 month low of $3.59 and a 12 month high of $13.41. The company has a market capitalization of $1,418.80, a price-to-earnings ratio of -13.67 and a beta of 2.17.
In other news, VP Richard J. Gregory sold 34,486 shares of the business’s stock in a transaction on Wednesday, February 21st. The shares were sold at an average price of $10.88, for a total transaction of $375,207.68. Following the completion of the sale, the vice president now owns 239,094 shares of the company’s stock, valued at approximately $2,601,342.72. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO David Brannon Johnston sold 10,000 shares of the business’s stock in a transaction on Thursday, March 15th. The shares were sold at an average price of $11.53, for a total transaction of $115,300.00. Following the sale, the chief financial officer now directly owns 190,690 shares of the company’s stock, valued at approximately $2,198,655.70. The disclosure for this sale can be found here. In the last three months, insiders have sold 229,930 shares of company stock valued at $2,515,150. Insiders own 6.51% of the company’s stock.
Several hedge funds have recently modified their holdings of IMGN. BlackRock Inc. grew its position in shares of ImmunoGen by 54.7% during the 4th quarter. BlackRock Inc. now owns 8,470,097 shares of the biotechnology company’s stock valued at $54,294,000 after acquiring an additional 2,996,116 shares during the period. Redmile Group LLC boosted its holdings in ImmunoGen by 35.3% in the 4th quarter. Redmile Group LLC now owns 10,906,962 shares of the biotechnology company’s stock worth $69,914,000 after buying an additional 2,845,465 shares during the period. Two Sigma Investments LP boosted its holdings in ImmunoGen by 168.9% in the 4th quarter. Two Sigma Investments LP now owns 1,020,089 shares of the biotechnology company’s stock worth $6,539,000 after buying an additional 640,669 shares during the period. Two Sigma Advisers LP bought a new position in ImmunoGen in the 4th quarter worth $3,805,000. Finally, Renaissance Technologies LLC boosted its holdings in ImmunoGen by 108.5% in the 4th quarter. Renaissance Technologies LLC now owns 1,093,240 shares of the biotechnology company’s stock worth $7,008,000 after buying an additional 568,900 shares during the period. 78.24% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This story was first posted by Week Herald and is the sole property of of Week Herald. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://weekherald.com/2018/04/20/immunogen-imgn-receives-consensus-rating-of-hold-from-brokerages.html.
ImmunoGen Company Profile
ImmunoGen, Inc, a clinical-stage biotechnology company, focuses on developing antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm, as well as coltuximab ravtansine, a CD19-targeting ADC, which is in Phase II trial for DLBCL.
Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.